Pfizer has made its fourth and final proposal to acquire AstraZeneca in a transaction valued at $120 billion, with 45% in cash. This latest offer represents a 45% increase of the total price and values AstraZeneca shares at £55 ($92.48) each. AstraZeneca declined to comment, but is reviewing the statement Pfizer issued.   Pfizer set forth terms of an improved proposal with a value of £53.50, with Pfizer and AstraZeneca shareholders owning approximately 74% and 26%, respectively, of the combined ...